Tic

New Advances in Gastric Diagnostics: Smaller is Better

In recent years, miniaturization has opened up exciting possibilities in the area of gastric diagnostics. New technology may make routine GI diagnostic procedures as simple as swallowing a vitamin pill-sized encapsulated unit in the not-too-far future, and the present reality is that these units are becoming valuable adjuncts to traditional diagnostics. Capsule endoscopy (enteroscopy...

Monitoring Options Expand for Therapeutic Agents and Drugs of Abuse

In keeping with the recent proliferation of rapid, easy-to-use diagnostic tests, many assays and collection products have entered the marketplace to help clinicians assess dosage appropriateness of therapeutic drugs and to screen for the presence of drugs of abuse. Some of these products require laboratory support while many simple test kits are suitable for point of care use by medical profe...

Genetic Analysis Systems Enter the Clinical Mainstream

Like many other diagnostic regimes that were previously restricted to large specialty laboratories, genetic analysis is entering the clinical mainstream. Smaller, simpler analyzer systems are now suitable and affordable for hospital or large physicians group labs, while some genetic test kits are becoming available for primary point of care locations such as clinics and physician offices.<...

West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak

WNVis a positive single-stranded RNA flavivirus of about 11 kb. It primarily infe...

Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy

Contributing Editor With over 200,000 new cases and 40,000 deaths per year, breast cancer undoubtedly qualifies as one of Americas most serious health problems. Recently, efforts to develop early detection methods and more effective therapy have made important progress. This is particularly...

Managing Preanalytical Processes for Patient Safety

Contributing Editor Positive patient identification (ID) is a major put by healthcare accrediting bodies for the past few years. Until recently, the costs associated with hardware and software were beyond the reach of the average hospital or laboratory. Today there are multiple vendors with devices that can be integra...

Low-Density Cholesterol Subfractions: Not all LDL-C Particles are Created Equal

Medical conventions are challenged every day. Already in the new year, the effectiveness of cold medicine and the gold standard in breast cancer treatment have been challenged. Standards in cholesterol testing are the latest casualty of medical innovation. For years, cholesterol has been measured by a simple panel o...

Hematology Analyzers Simple, Sophisticated Technology Serving All Patients

Some form of electronic hematology analyzer is found at the center of most clinical laboratories. A blood cell count is usually the first screening test used to assess general health, rule out anemia or infection, and monitor cancer patients during the course of chemotherapy. It is difficult to imagine medical...

Non-Invasive Diagnostic Tests for Celiac Disease

Celiac disease (CD) is an autoimmune inflammatory disease of the small intestine that is triggered in genetically susceptible persons by the ingestion of the gluten-containing grains wheat, rye, barley, and possibly oats. The condition is thought to result from the activation of both a T-cell and B-cell immune respons...

Cell Therapeutics, Inc. Management to Discuss Today's Announcement of Interim Pixantrone Study Results

SEATTLE, July 11, 2007 /PRNewswire-FirstCall/ -- On Wednesday,July 11, 2007, at 1:30 p.m. Pacific/4:30 p.m. Eastern/10:30 p.m.Central European Time members of Cell Therapeutics, Inc.'s (CTI)management team will host a conference call to discuss today'sannouncement of the interim results of its phase II/III RAPID trialcomparing CHOP-R to CPOP-R, in which pixantrone is substituted fordoxor...

Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis

RIDGEFIELD, Conn., July 11, 2007 /PRNewswire/ -- Phase 3 resultsfrom the RE-NOVATE(TM) trial demonstrated that oral dabigatranetexilate once daily, administered for an average of 33 days, wasnon-inferior to enoxaparin, also administered for an average of 33days, in preventing venous thromboembolism (VTE) and all-causemortality after total hip replacement surgery. In this trial, therate o...

Antibiotics Don't Prevent Future Urinary Tract Infections, May Cause Resistance in Future Infections

PHILADELPHIA, July 10, 2007 /PRNewswire-USNewswire/ -- After afirst childhood urinary tract infection (UTI), daily antibioticsmay not prevent another such infection, and may actually increasethe risk that the next urinary tract infection is caused byresistant bacteria, according to a new study in the July 11 issueof the Journal of the American Medical Association. In the first larg...

Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting

GENEVA, July 11, 2007 /PRNewswire/ -- InspirationBiopharmaceuticals today announced the presentation of preclinicaldata supporting the development of new, proprietary forms ofrecombinant Factor IX to treat patients with Hemophilia B. The datawere highlighted in an oral presentation and a poster session atthe XXIst Congress of the International Society on Thrombosis andHaemostasis (ISTH)...

BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Jul 11, 2007 - BioSantePharmaceuticals, Inc. (Amex: BPA) today announced new positiveresults demonstrating that its calcium phosphate (CaP)nanoparticle-based vaccine adjuvant, BioVant(TM), may serve as aneffective vaccine adjuvant for the development of a dose sparingvaccine against H5N1 avian flu, widely known as bird flu. The new results are based on...

Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis

SAN FRANCISCO, July 10, 2007 /PRNewswire/ -- PortolaPharmaceuticals, Inc. announced positive Phase II data on its leadcompound, PRT054021, an oral Factor Xa inhibitor, today at the XXICongress of the International Society on Thrombosis and Haemostasis(ISTH) in Geneva, Switzerland. The EXPERT trial showed thatPRT054021 was safe, effective, and well tolerated for theprevention of venous th...

Halozyme Therapeutics' Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society

- Co-Injection of rHuPH20 with Humira Estimated to Increase theMaximal Steady State Subcutaneous Bioavailability from 64% to 100%- SAN DIEGO, July 09, 2007 /PRNewswire-FirstCall/ -- HalozymeTherapeutics, Inc. , a biopharmaceutical company developing andcommercializing recombinant human enzymes, today announced thatfinal results of the Enhanze(TM) Technology clinical trialdemonstrating im...

CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa

-- New Preclinical Information May Correlate with Clinical HbA1cReductions Observed in Phase 3 CARISA and MERLIN TIMI-36 ClinicalTrials -- PALO ALTO, Calif., July 9, 2007 /PRNewswire-FirstCall/ -- CVTherapeutics, Inc. announced today that researchers have completedpreliminary preclinical studies showing that ranolazine increasedglucose stimulated insulin secretion in pancreatic beta cells...

Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone

- Results Fail to Demonstrate Meaningful Placebo Adjusted WeightLoss; Obesity Program to be Discontinued NEW YORK, July 09, 2007 /PRNewswire-FirstCall/ -- ManhattanPharmaceuticals, Inc. today announced results of the company's twoPhase 2a clinical trials of oral Oleoyl-estrone (OE). The resultsof both randomized, double-blind, placebo-controlled studies, onein common obesity and the other...

Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate

FREISING-WEIHENSTEPHAN, Germany, July 10, 2007 /PRNewswire/ --Pieris AG, a bio-pharmaceutical company developing Anticalins(R), anovel class of targeted human protein therapeutics, today announcedsignificant progress in validating novel, effective products forthe potential treatment of asthma. In studies of its proprietaryPRS-060 Anticalin(R) candidate, the Company reports that theprotei...

BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease

WAKEFIELD, Mass.--(BUSINESS WIRE)--Jul 10, 2007 - BusinessWeekpublished an article on July 6 discussing the race bypharmaceutical and biotechnology companies to be first to bring tomarket an effective angiogenesis treatment for cardiovasculardisease. While angiogenesis therapies are being pursued bySanofi-Aventis, Boston Scientific, Baxter, and Genzyme, amongothers, the article highlights a...

Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting System's Success in Mouse Model Reported in Cancer Cell

HOUSTON, July 9, 2007 - A molecularly engineeredtherapy selectively embeds a gene in pancreatic cancer that shrinksor eradicates tumors, inhibits metastasis, and prolongs survivalwith virtually no toxicity, researchers from The University ofTexas M. D. Anderson Cancer Center report in the July 9 edition ofCancer Cell. "This vehicle, or vector, is so targeted and robust in itscanc...

Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference

MALVERN, Pa., June 28, 2007 /PRNewswire-FirstCall/ -- AuxiliumPharmaceuticals, Inc. today announced that Mr. Armando Anido, ChiefExecutive Officer and President, and Mr. Jim Fickenscher, ChiefFinancial Officer, will participate in the 2007 CEUT EmergingGrowth Opportunities Conference to be held July 10 through July 12,2007 at the Mandarin Oriental Hotel in New York City. Mr. Anido issche...

Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference

SOUTH SAN FRANCISCO, Calif., July 03, 2007/PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. todayannounced that Eric Bjerkholt, Sunesis' Senior Vice President,Corporate Development and Finance, will present a company update atthe C. E. Unterberg, Towbin Emerging Growth Conference on July 12,2007 at 9:00 a.m. Eastern Time in New York, NY. Interested parties may access the webc...

EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--Jul 3, 2007 - EPIXPharmaceuticals, Inc. (NASDAQ:EPIX) today announced that Michael G.Kauffman, M.D., Ph.D., chief executive officer of EPIX, isscheduled to present at the C.E. Unterberg, Towbin Emerging GrowthOpportunities Conference on Tuesday, July 10, 2007 at 1:30 p.m.(EDT) at the Mandarin Oriental Hotel in New York, NY. The presentation will be webca...

GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference

FRAMINGHAM, Mass.--(BUSINESS WIRE)--Jul 5, 2007 - GTCBiotherapeutics, Inc. ("GTC", Nasdaq: GTCB) announced today thatGeoffrey Cox, Ph.D., GTC's Chairman and CEO, is scheduled topresent on Wednesday, July 11, 2007 at 9:00 a.m. during the C.E.Unterberg, Towbin Emerging Growth Life Opportunities Conference.The conference is being held at the Mandarin Oriental Hotel, NewYork, New York from July...

Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings

NEWTON, Mass.--(BUSINESS WIRE)--Jul 9, 2007 - Pro-Pharmaceuticals,Inc. (Amex: PRW), a company "Advancing Drugs ThroughGlycoscience(R)", today updated the progress of its Phase IIclinical trial for first-line treatment of metastatic, unresectablecolorectal cancer patients who are unable to tolerate irinotecanand/or oxaliplatin, and its Phase II clinical trial for first-linetreatment of bilia...

Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer

- First prospective biomarker trial in non-small cell lung cancer - LOS ANGELES, July 09, 2007 /PRNewswire-FirstCall/ -- ResponseGenetics, Inc. today announced that positive Phase III clinicaldata published in the July 1 issue of the Journal of ClinicalOncology suggests that low expression of the biomarkerExcision-Repair Cross-Complementing 1 (ERCC-1) in patient biopsieswith advanced non-...

BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease

WAKEFIELD, Mass.--(BUSINESS WIRE)--Jul 6, 2007 - BusinessWeek todaypublished an article discussing the race by pharmaceutical andbiotechnology companies to be first to bring to market an effectiveangiogenesis treatment for cardiovascular disease. Whileangiogenesis therapies are being pursued by Sanofi-Aventis, BostonScientific, Baxter, and Genzyme, among others, the articlehighlights a very...

Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine

- Phase II Results Published in the Journal of Clinical Oncology - NEW YORK, July 06, 2007 /PRNewswire-FirstCall/ -- Results from aPhase II study - which will be published in the August 10, 2007issue of the Journal of Clinical Oncology (JCO) and are nowavailable as an Early Release Article at <a target="_blank" href="http://www.jco.org/">www.jco.org - demonstrate thatixabepilone, a Br...

NIEHS Researchers Identify Enzyme Critical in DNA Replication

BETHESDA, Md., July 5, 2007--In this weeks issue of Science,researchers from the National Institute of Environmental HealthSciences (NIEHS) and Umeö University in Sweden report animportant discovery about a critical new role that an enzyme calledDNA polymerase epsilon plays in replicating DNA in higher organismssuch as yeast and perhaps even humans. The study places us one ste...

Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea

LAINATE, Italy - July 4, 2007 - Cosmo Pharmaceuticals SpA(SWX:COPN) announced today positive preliminary results from itsphase II/III study with CB-01-11 (Rifamycin SV MMX(tm)) ininfectious diarrhoea. CB-01-11 is a broad spectrum, semi-syntheticantibiotic that is not absorbed when taken in tablet form. Throughthe use of Cosmo's MMX(tm) technology, wh...

Peer Reviewed Journal Article Indicates Repros' Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer

THE WOODLANDS, Texas--(BUSINESS WIRE)--Jul 5, 2007 - ReprosTherapeutics Inc. (NasdaqGM:RPRX) today announced that an articlehas been published in the July 1, 2007 issue of Oncology Reportsindicating a potential for a new approach to the treatment ofbreast cancer using Proellex. The article reviews the findings froma study conducted in an accepted in vivo rat model of breastcancer. The study...

From Clinical Cancer Research: Rethinking Therapeutic Cancer Vaccine Trials

PHILADELPHIA, July 3, 2007-- Ongoing therapeutic cancer vaccinetrials have yet to show evidence of vaccines spurring apatient’s immune system to shrink tumors -- yet patients whoreceive these vaccines in trials tend to live longer and respondbetter to subsequent treatment. In the July 1 issue of ClinicalCancer Research, a journal of the American Association for CancerResearch, a te...

Skin Rash Actually Signifies Better Outcomes for Pancreatic and Lung Cancer Patients

PHILADELPHIA, July 3, 2007-- – The appearance of arash in cancer patients treated with erlotinib (Tarceva) isstrongly associated with longer survival, according to researchersfrom the drug’s developer, OSI Pharmaceuticals, Inc. This isnot the first time that rash has been associated with a survivaladvantage with EGFR inhibitors – a class of drugs whichincludes erlotinib...

Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics

PHILADELPHIA, July 3, 2007 ? Researchers in Slovakia havebeen able to derive mesenchymal stem cells from human adipose, orfat, tissue and engineer them into “suicide genes” that seek out and destroy tumors like tiny homing missiles. This gene therapy approach is a novel way to attack smalltumor metastases that evade current detection techniques andtreatments, the researchers...

Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)

SOUTH SAN FRANCISCO, July 02, 2007 /PRNewswire/ -- PortolaPharmaceuticals, Inc. announced today that it will present clinicaland preclinical data on its oral Factor Xa inhibitor and on itsintravenous and oral ADP receptor antagonist at the XXI Congress ofthe International Society of Thrombosis and Haemostasis (ISTH) inGeneva, Switzerland on July 6 through July 12, 2007. The EXPERT...

Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections

DENVER--(BUSINESS WIRE)--Jul 2, 2007 - Ceragenix Pharmaceuticals,Inc. (OTCBB:CGXP), a biopharmaceutical company focused oninfectious disease and dermatology, today announced thatresearchers at the University of Pennsylvania led by Dr. PaulJanmey and Dr. Robert Bucki, in collaboration with Dr. Paul B.Savage of Brigham Young University, have demonstrated in a seriesof in vitro experiments tha...

Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival

- New Data from Phase III Intergroupe Francophone du Myelome (IFM)Trial Presented During IMW - CAMBRIDGE, Mass., July 02, 2007 /PRNewswire-FirstCall/ --Millennium Pharmaceuticals, Inc. today reported that new data werepresented on the comparative Phase III clinical trial evaluating aVELCADE based therapy in newly diagnosed multiple myeloma (MM)patients. As induction therapy prior to stem...

Cytokinetics Reports Additional Clinical Trials Data for Ispinesib

SOUTH SAN FRANCISCO, CA June 28, 2007 - Cytokinetics,Incorporated (Nasdaq: CYTK) announced results from the analyses ofthree Phase II clinical trials of ispinesib administered asmonotherapy, one in patients with hepatocellular cancer, one inpatients with melanoma, and one in patients with hormone-refractoryprostate cancer. I...

Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstrom's Macroglobulinemia

Data presented at the 11th International Myeloma Workshop held inKos, Greece demonstrates clinical activity of perifosine incombination with bortezomib, dexamethasone and lenalidomide plusdexamethasone, in patients with relapsed/refractory multiplemyeloma, and as a single agent in patients with relapsed/refractoryWaldenstrom's macroglobulinemia NEW YORK, June 29, 2007 /PRNewswire-FirstCal...